CONVERSION OF BIOHIT OYJ SERIES A SHARES INTO SERIES B SHARES, AND NOTIFICATION
BIOHIT OYJ STOCK EXCHANGE RELEASE 29 AUGUST 2008 AT 09:30 AM
CONVERSION OF BIOHIT OYJ SERIES A SHARES INTO SERIES B SHARES, AND NOTIFICATION OF A CHANGE IN SHARE OWNERSHIP IN ACCORDANCE WITH THE SECURITIES MARKETS ACT, CHAPTER 2, SECTION 10 On 28 August 2008, at Professor Pentti Sipponen's request and in accordance with the Articles of Association, Biohit Oyj's Board of Directors decided to convert 900,000 Series A shares owned by Sipponen into the equivalent number of Series B shares. The new Series B shares should be available for public trading on 5 September 2008, that is, on the day after they are registered in the Trade Register. After the share conversion, the number of shares in each class and the votes conferred will be as follows: -------------------------------------------------------------------------------- | | Number of shares | Votes conferred | -------------------------------------------------------------------------------- | Series A shares | 2,975,500 | 59,510,000 | -------------------------------------------------------------------------------- | Series B shares | 9,962,127 | 9,962,127 | -------------------------------------------------------------------------------- | Total | 12,937,627 | 69,472,127 | -------------------------------------------------------------------------------- After the Board's decision, on 28 August 2008 Biohit Oyj received notification that the combined share of voting rights conferred by shares owned by Professor Pentti Sipponen and Patolab Oy - a company in his control - had fallen to under one twentieth as a result of the conversion. On 28 August 2008, Biohit Oyj also received notification that the combined share of voting rights conferred by shares owned by Professor Osmo Suovaniemi, Biocosmos Oy and Interlab Oy - two companies in his control - had risen to over two thirds as a result of the conversion. In accordance with the Securities Markets Act, Chapter 2, Section 10, Biohit Oyj is issuing notification that the following changes have occurred in the percentage of shares and votes held by Pentti Sipponen, Osma Suovaniemi and companies in their control: -------------------------------------------------------------------------------- | | No. | % of shares | % of votes | -------------------------------------------------------------------------------- | Osmo Suovaniemi | | | | -------------------------------------------------------------------------------- | Series A shares | 2,265,340 | 17.51 | 65.22 | -------------------------------------------------------------------------------- | Series B shares | 965,207 | 7.46 | 1.39 | -------------------------------------------------------------------------------- -------------------------------------------------------------------------------- | Biocosmos Oy | | | | | (Business ID 0551234-7) | | | | -------------------------------------------------------------------------------- | Series B shares | 693,735 | 5.36 | 1.00 | -------------------------------------------------------------------------------- -------------------------------------------------------------------------------- | Interlab Oy | | | | | (Business ID 0201370-2) | | | | -------------------------------------------------------------------------------- | Series B shares | 572,762 | 4.43 | 0.82 | -------------------------------------------------------------------------------- -------------------------------------------------------------------------------- | Total | 4,497,044 | 34.76 | 68.43 | -------------------------------------------------------------------------------- -------------------------------------------------------------------------------- | Pentti Sipponen | | | | -------------------------------------------------------------------------------- | Series B shares | 914,300 | 7.07 | 1.32 | -------------------------------------------------------------------------------- -------------------------------------------------------------------------------- | Patolab Oy | | | | | (Business ID 0427816-5) | | | | -------------------------------------------------------------------------------- | Series B shares | 12,300 | 0.10 | 0.02 | -------------------------------------------------------------------------------- | Total | 926,600 | 7.16 | 1.33 | -------------------------------------------------------------------------------- Biohit Oyj's share capital consists of 12 937 627 shares. Series A shares confer twenty (20) votes and Series B shares confer one (1) vote. In payment of dividends, however, a dividend of two (2) per cent higher than the nominal value is paid for Series B shares than is paid for Series A shares. Biohit Oyj Osmo Suovaniemi President and CEO Further information: Osmo Suovaniemi, M.D., Ph.D., Professor President & CEO Tel: +358-9-773 861 GSM: +358-40-745 5605 Email: osmo.suovaniemi@biohit.com Distribution: Helsinki Exchanges Central storage facility (www.oam.fi) Press www.biohit.com About Biohit Oyj Biohit Oyj develops, manufactures and markets liquid handling products and diagnostic test systems for use in research, health care and industrial laboratories. Liquid handling products include electronic and mechanical pipettes and dispensers, and disposable tips, as well as pipette maintenance and calibration services. Diagnostics business comprises products and analysis systems for diagnosing, screening and prevention of gastrointestinal diseases, e.g. the blood-sample based GastroPanel and GastroView, for diagnosing diseases of the stomach and associated risks, as well as biopsy specimen quick tests for the diagnosis of lactose intolerance and H. pylori infection. Biohit Oyj is headquartered in Finland. Biohit has subsidiaries in France, Germany, the UK, Russia, China, Japan and the USA. Additionally, Biohit's products are sold by approximately 450 distributors in 70 countries. Biohit's share (BIOBV) is quoted on the Helsinki Exchanges (OMX Helsinki). Read more at www.biohit.com